Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
General Mills, Inc. stock logo
GIS
General Mills
$71.17
+1.1%
$67.01
$60.33
$90.89
$39.99B0.154.05 million shs3.63 million shs
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$128.89
+1.6%
$124.44
$116.32
$147.87
$42.73B0.42.18 million shs2.71 million shs
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$731.32
+0.7%
$763.83
$370.68
$800.78
$690.11B0.342.28 million shs2.35 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
General Mills, Inc. stock logo
GIS
General Mills
+1.07%+5.73%+3.00%+9.92%-18.62%
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
+1.62%+2.74%+3.17%+3.18%-8.96%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
+0.69%-2.65%-5.10%+16.20%+89.83%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
General Mills, Inc. stock logo
GIS
General Mills
4.0304 of 5 stars
2.03.02.52.62.52.51.9
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
4.6366 of 5 stars
2.05.04.22.53.53.31.3
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
4.8282 of 5 stars
2.44.02.54.02.42.53.1

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
General Mills, Inc. stock logo
GIS
General Mills
2.06
Hold$72.181.41% Upside
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
2.00
Hold$131.852.29% Upside
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
2.84
Moderate Buy$728.05-0.45% Downside

Current Analyst Ratings

Latest GIS, KMB, and LLY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/22/2024
General Mills, Inc. stock logo
GIS
General Mills
Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$77.00 ➝ $77.00
4/15/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
4/12/2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$124.00 ➝ $132.00
4/11/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetNeutral ➝ Neutral$650.00 ➝ $723.00
4/3/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Erste Group Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Buy
4/2/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$675.00 ➝ $895.00
4/1/2024
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$815.00
3/28/2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Deutsche Bank Aktiengesellschaft
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetHold ➝ Hold$127.00 ➝ $132.00
3/28/2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$145.00 ➝ $152.00
3/28/2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingSector Perform ➝ Sector Perform$123.00
3/28/2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$125.00 ➝ $131.00
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
General Mills, Inc. stock logo
GIS
General Mills
$20.09B2.01$5.41 per share13.15$18.28 per share3.89
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$20.43B2.13$8.96 per share14.38$3.16 per share40.79
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$34.12B20.36$7.68 per share95.24$11.44 per share63.93

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
General Mills, Inc. stock logo
GIS
General Mills
$2.59B$4.3616.3215.312.4312.66%26.84%8.71%6/26/2024 (Estimated)
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$1.76B$5.2024.7917.783.778.63%260.47%12.72%4/23/2024 (Confirmed)
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.24B$5.80126.0939.531.5815.36%51.22%9.94%4/30/2024 (Confirmed)

Latest GIS, KMB, and LLY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/30/2024N/A
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.61N/A-$2.61N/AN/AN/A  
4/23/2024N/A
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$1.59$1.63+$0.04N/A$5.08 billion$5.15 billion  
3/20/2024Q3 24
General Mills, Inc. stock logo
GIS
General Mills
$1.05$1.17+$0.12$1.17$4.97 billion$5.10 billion    
2/6/202412/31/2023
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$2.30$2.49+$0.19$2.56$8.95 billion$9.35 billion    
1/24/202412/31/2023
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$1.53$1.51-$0.02$1.52$4.99 billion$5.00 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
General Mills, Inc. stock logo
GIS
General Mills
$2.363.32%+4.51%54.13%2 Years
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
$4.883.79%+3.32%93.85%53 Years
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
$5.200.71%+15.15%89.66%10 Years

Latest GIS, KMB, and LLY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
1/30/2024
General Mills, Inc. stock logo
GIS
General Mills
Quarterly$0.593.64%4/9/20244/10/20245/1/2024
1/24/2024
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
quarterly$1.223.91%3/7/20243/8/20244/2/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
General Mills, Inc. stock logo
GIS
General Mills
1.14
0.66
0.40
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
6.94
0.82
0.54
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
1.69
0.94
0.73

Ownership

Institutional Ownership

CompanyInstitutional Ownership
General Mills, Inc. stock logo
GIS
General Mills
75.71%
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
76.29%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
82.53%

Insider Ownership

CompanyInsider Ownership
General Mills, Inc. stock logo
GIS
General Mills
0.24%
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
0.62%
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
0.13%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
General Mills, Inc. stock logo
GIS
General Mills
34,000567.90 million566.54 millionOptionable
Kimberly-Clark Co. stock logo
KMB
Kimberly-Clark
41,000336.91 million334.83 millionOptionable
Eli Lilly and Company stock logo
LLY
Eli Lilly and Company
43,000950.16 million948.93 millionOptionable

GIS, KMB, and LLY Headlines

SourceHeadline
Eli Lilly and Company (NYSE:LLY) is Jennison Associates LLCs 5th Largest PositionEli Lilly and Company (NYSE:LLY) is Jennison Associates LLC's 5th Largest Position
marketbeat.com - April 23 at 8:29 AM
Hagens Berman Signals Major Turning Point in Insulin Fair Pricing Class-Action LawsuitHagens Berman Signals Major Turning Point in Insulin Fair Pricing Class-Action Lawsuit
businesswire.com - April 23 at 5:00 AM
Eli Lilly and Company (LLY) to Release Quarterly Earnings on TuesdayEli Lilly and Company (LLY) to Release Quarterly Earnings on Tuesday
americanbankingnews.com - April 23 at 2:36 AM
Eli Lilly and Company (NYSE:LLY) Holdings Reduced by Illinois Municipal Retirement FundEli Lilly and Company (NYSE:LLY) Holdings Reduced by Illinois Municipal Retirement Fund
marketbeat.com - April 22 at 9:59 PM
Eli Lilly (LLY) Advances But Underperforms Market: Key FactsEli Lilly (LLY) Advances But Underperforms Market: Key Facts
zacks.com - April 22 at 6:51 PM
Lilly to buy injectable drug plant in manufacturing ramp-upLilly to buy injectable drug plant in manufacturing ramp-up
biopharmadive.com - April 22 at 6:50 PM
Eli Lilly and Company (NYSE:LLY) Trading 0.2% Higher Eli Lilly and Company (NYSE:LLY) Trading 0.2% Higher
marketbeat.com - April 22 at 1:55 PM
Nexus Pharmaceuticals sells Pleasant Prairie facility to pharmaceutical giant Eli LillyNexus Pharmaceuticals sells Pleasant Prairie facility to pharmaceutical giant Eli Lilly
biztimes.com - April 22 at 1:50 PM
Eli Lilly buys injectable medicine manufacturing facility in WisconsinEli Lilly buys injectable medicine manufacturing facility in Wisconsin
msn.com - April 22 at 1:50 PM
7 High-Flying Stocks That Are Majorly Overdue for a Pullback7 High-Flying Stocks That Are Majorly Overdue for a Pullback
investorplace.com - April 22 at 1:43 PM
Eli Lilly to acquire manufacturing facility from Nexus PharmaEli Lilly to acquire manufacturing facility from Nexus Pharma
reuters.com - April 22 at 11:54 AM
Severity of sleep apnea comes down with Eli Lillys weight-loss drugSeverity of sleep apnea comes down with Eli Lilly's weight-loss drug
malaysiasun.com - April 22 at 8:49 AM
Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY)Analysts Offer Insights on Healthcare Companies: Abbott Labs (ABT) and Eli Lilly & Co (LLY)
markets.businessinsider.com - April 22 at 8:49 AM
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs?
marketbeat.com - April 22 at 6:05 AM
Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (LLY)Wegovy vs. Zepbound: Who Wins the Battle of the GLP-1 Drugs? (LLY)
marketbeat.com - April 22 at 6:05 AM
Eli Lilly And The Alzheimers Dilemma (Rating Upgrade)Eli Lilly And The Alzheimer's Dilemma (Rating Upgrade)
seekingalpha.com - April 22 at 12:58 AM
Duality Advisers LP Acquires 2,253 Shares of Eli Lilly and Company (NYSE:LLY)Duality Advisers LP Acquires 2,253 Shares of Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 22 at 12:32 AM
11 Hot Growth Stocks To Buy Right Now11 Hot Growth Stocks To Buy Right Now
finance.yahoo.com - April 21 at 11:29 AM
Eli Lilly and Company (NYSE:LLY) Trading Down 2%Eli Lilly and Company (NYSE:LLY) Trading Down 2%
americanbankingnews.com - April 21 at 3:56 AM
Criterion Capital Advisors LLC Takes $1.34 Million Position in Eli Lilly and Company (NYSE:LLY)Criterion Capital Advisors LLC Takes $1.34 Million Position in Eli Lilly and Company (NYSE:LLY)
marketbeat.com - April 20 at 5:00 PM
Eli Lilly’s Zepbound in shortage months after approvalEli Lilly’s Zepbound in shortage months after approval
msn.com - April 20 at 12:31 PM
Zepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly saysZepbound shortage: Weight loss drugs’ limited availability to continue, Eli Lilly says
msn.com - April 20 at 12:31 PM
Missed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant PotentialMissed Out on Eli Lilly and Novo Nordisk? This Small Biotech Has a Promising GLP-1 Drug With Significant Potential
fool.com - April 20 at 8:30 AM
Most people on weight loss drugs are spending less on restaurants and takeout, survey saysMost people on weight loss drugs are spending less on restaurants and takeout, survey says
cnbc.com - April 20 at 8:00 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

General Mills logo

General Mills

NYSE:GIS
General Mills, Inc. manufactures and markets branded consumer foods worldwide. The company operates through four segments: North America Retail; International; Pet; and North America Foodservice. It offers grain, ready-to-eat cereals, refrigerated yogurt, soup, meal kits, refrigerated and frozen dough products, dessert and baking mixes, bakery flour, frozen pizza and pizza snacks, snack bars, fruit and salty snacks, ice cream and frozen desserts, nutrition bars, and savory snacks, as well as various organic products, including frozen and shelf-stable vegetables. It also manufactures and markets pet food products, including dog and cat food. The company markets its products under the Annie's, Betty Crocker, Bisquick, Blue Buffalo, Blue Basics, Blue Freedom, Bugles, Cascadian Farm, Cheerios, Chex, Cinnamon Toast Crunch, Cocoa Puffs, Cookie Crisp, EPIC, Fiber One, Fruit by the Foot, Fruit Gushers, Fruit Roll-Ups, Gardetto's, Go-Gurt, Gold Medal, Golden Grahams, Häagen-Dazs, Kitano, Kix, Lärabar, Latina, Lucky Charms, Muir Glen, Nature Valley, Nudges, Oatmeal Crisp, Old El Paso, Pillsbury, Progresso, Raisin Nut Bran, Total, Top Chews Naturals, Totino's, Trix, True Chews, Wanchai Ferry, Wheaties, Wilderness, Yoki, Reese's Puffs, Green Giant, and Yoplait trademarks. It sells its products directly, as well as through broker and distribution arrangements to grocery stores, mass merchandisers, membership stores, natural food chains, e-commerce retailers, commercial and noncommercial foodservice distributors and operators, restaurants, convenience stores, and pet specialty stores, as well as drug, dollar, and discount chains. In addition, the company operates ice cream parlors. General Mills, Inc. was founded in 1866 and is headquartered in Minneapolis, Minnesota.
Kimberly-Clark logo

Kimberly-Clark

NYSE:KMB
Kimberly-Clark Corporation, together with its subsidiaries, manufactures and markets personal care and consumer tissue products in the United States. It operates through three segments: Personal Care, Consumer Tissue, and K-C Professional. The company's Personal Care segment offers disposable diapers, training and youth pants, swimpants, baby wipes, feminine and incontinence care products, reusable underwear, and other related products under the Huggies, Pull-Ups, Little Swimmers, GoodNites, DryNites, Sweety, Kotex, U by Kotex, Intimus, Thinx, Poise, Depend, Plenitud, Softex, and other brand names. Its Consumer Tissue segment provides facial and bathroom tissues, paper towels, napkins, and related products under the Kleenex, Scott, Cottonelle, Viva, Andrex, Scottex, Neve, and other brand names. The company's K-C Professional segment offers wipers, tissues, towels, apparel, personal protective equipment, soaps, and sanitizers under the Kleenex, Scott, WypAll, Kimtech, and KleenGuard brands. It also sells household use products directly to supermarkets, mass merchandisers, drugstores, warehouse clubs, variety and department stores, and other retail outlets, as well as through other distributors and e-commerce; and away-from-home use products directly to distributors, manufacturing, lodging, office building, food service, and public facilities, as well as through e-commerce. Kimberly-Clark Corporation was founded in 1872 and is headquartered in Dallas, Texas.
Eli Lilly and Company logo

Eli Lilly and Company

NYSE:LLY
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.